222 related articles for article (PubMed ID: 7534141)
21. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
Chen HR; Ji SQ; Wang HX; Yan HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
23. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias.
Rambaldi A; Viero P; Bassan R; Buelli M; Rossi A; Bellavita P; Spinelli O; Amaru R; Micheletti M; Borleri G; Cortelazzo S; Comotti B; Barbui T
Leukemia; 1996 May; 10(5):860-5. PubMed ID: 8656684
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
25. Possible clinical benefits of the use of peripheral blood stem cells over bone marrow in the allogeneic transplantation setting for the treatment of childhood leukemia.
Matsubara H; Makimoto A; Takayama J; Higa T; Saito T; Kanda Y; Tanosaki R; Mineishi S; Ohira M; Takaue Y
Jpn J Clin Oncol; 2001 Jan; 31(1):30-4. PubMed ID: 11256838
[TBL] [Abstract][Full Text] [Related]
26. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
27. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
[TBL] [Abstract][Full Text] [Related]
28. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism.
Beelen DW; Ottinger HD; Elmaagacli A; Scheulen B; Basu O; Kremens B; Havers W; Grosse-Wilde H; Schaefer UW
Blood; 1997 Dec; 90(12):4725-35. PubMed ID: 9389688
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Bishop MR; Tarantolo SR; Geller RB; Lynch JC; Bierman PJ; Pavletic ZS; Vose JM; Kruse S; Dix SP; Morris ME; Armitage JO; Kessinger A
Blood; 2000 Jul; 96(1):80-5. PubMed ID: 10891434
[TBL] [Abstract][Full Text] [Related]
30. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic peripheral blood stem cell transplantation and early detection of donor engraftment by polymerase chain reaction.
Tzeng CH; Lyou JY; Lin JS; Chen YR; Hu HY; Yung CH; Wang SY; Lee JC
J Formos Med Assoc; 1998 Apr; 97(4):252-60. PubMed ID: 9585676
[TBL] [Abstract][Full Text] [Related]
32. Transplantation of allogeneic CD34+ blood cells.
Link H; Arseniev L; Bähre O; Kadar JG; Diedrich H; Poliwoda H
Blood; 1996 Jun; 87(11):4903-9. PubMed ID: 8639865
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.
Rosenfeld C; Collins R; Piñeiro L; Agura E; Nemunaitis J
J Clin Oncol; 1996 Apr; 14(4):1314-9. PubMed ID: 8648389
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
35. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
36. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors.
Berger C; Bertz H; Schmoor C; Behringer D; Potthoff K; Mertelsmann R; Finke J
Bone Marrow Transplant; 1999 May; 23(10):983-90. PubMed ID: 10373062
[TBL] [Abstract][Full Text] [Related]
37. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
[TBL] [Abstract][Full Text] [Related]
38. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic peripheral blood progenitor cells mobilized by G-CSF (filgrastim) for a second transplant in a patient with acute myeloid leukemia in relapse.
Martínez JA; Picón I; Carral A; de la Rubia J; Sanz GF; Sanz MA
Bone Marrow Transplant; 1995 Jan; 15(1):149-51. PubMed ID: 7537999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
